Hormone receptor positive
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
... retrospective, hormone receptor-positive (cases with positivity for estrogen and/or progesterone receptor by CLIA-cerified immunohistochemistry), stage I-III BC cohort (N = 362) was extracted ...
9
Aberrations in translational regulation are associated with poor prognosis in hormone receptor positive breast cancer
... III hormone receptor-positive breast cancer treated at Hospital Clinico Universitario de Valencia, ...on hormone receptor-positive status, availability of adequate frozen tissue, ...
11
Metformin increases survival in hormone receptor positive, HER2 positive breast cancer patients with diabetes
... The results of this study confirmed that treatment with metformin after breast cancer diagnosis in diabetic pa- tients improves DFS and reduces mortality. The most important finding was that the survival difference ac- ...
14
Comparative study of neoadjuvant chemotherapy in hormone receptor positive and negative locally advanced breast carcinoma
... This is certify that this dissertation work title COMPARATIVE STUDY OF NEOADJUVANT CHEMOTHERAPY IN HORMONE RECEPTOR POSITIVE AND NEGATIVE LOCALLY ADVANCED BREAST CARCINOMA of the candidate ...
124
Considerations for payers in managing hormone receptor-positive advanced breast cancer
... Abstract: Breast cancer (BC) is the second most common cause of death in women. In 2010, the direct cost associated with BC care in the US was $16.5 billion, the highest among all cancers. By the year 2020, at the ...
9
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
... hormone-receptor positive, HER2-negative breast cancer [11]. Patients were eligible if their cancer had relapsed or progressed with prior endocrine therapy. Both pre- and postmenopausal women were ...
10
Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study
... the hormone receptor-positive and HER2 - ...in hormone receptor- positive and HER2 - breast cancer patients and also inves- tigated whether it is necessary to further subtype ...
7
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
... factor receptor-2 (HER2-positive [HER2+]) tend to be biologically aggressive and associated with a poor prognosis, even those that coexpress receptors for estrogen and/or progesterone (hormone ...
12
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
... with hormone receptor positive, metastatic breast cancer with prior disease progression during aromatase inhibitor therapy (n = 8) in a phase I/II trial with the multiple tyrosine kinase inhibitor ...
10
Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
... We examined dose–response relationships between risk fac- tors and levels of KI67, by using the median % positive cells in each quartile of KI67 as constraints in an ordered polytomous logistic regression model. ...
13
Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
... the receptor stable group and the no receptor conversion group according to pre- and post-NAC ER and PR ...had positive-to-negative change, and 5 ...negative-to- positive change in HER2 status ...
9
Hormone therapy for breast cancer
... the hormone receptor positive breast ...a hormone receptor positive breast cancer, it has more benefits and fewer side effects than Tamoxifen, such as blood clots, stroke, and ...
7
mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials
... Individual studies characteristics and results All studies were conducted on postmenopausal women with hormone receptor positive and HER2- negative advanced breast cancer. One phase II trial ...
12
Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer
... Based on the accumulating evidence of FFAR4 and its ligands in breast tissues, we hypothesized that breast cancer cells may utilize fatty acids in situ as stimulating signals via expressing FFAR4 and therefore exert ...
18
Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement
... A total of 1,110 patients with hormone receptor-positive breast cancer met the patient selection criteria. The demographic and clinical characteristics are summarized in Table S1. In our study, 92.6% ...
11
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
... metastatic hormone receptor-positive breast cancer poses a challenge due to the inevitable development of endocrine ...resistance. Hormone resistance is associated with a complex interaction ...
10
Management of patients with hormone receptor–positive breast cancer with visceral disease: challenges and treatment options
... with hormone receptor–positive (HR+) advanced breast cancer (ABC), yet many tumors are either intrinsically resistant or develop resistance to these ...
10
Intercomparison of Tamoxifen and Exemestane Hormone Treatment in Receptor Positive Breast Carcinoma Patients
... For more than 20 years, a 3-5 year course of adjuvant tamoxifen has been the standard endocrine treatment for women with hormone receptor positive breast cancer. However, this standard is being ...
7
Human epidermal growth factor receptor 2 positive microinvasive breast carcinoma with a highly aggressive course: a case report
... a positive sentinel node, an axil- lary dissection should be performed ...of positive axillary nodes, adjuvant systemic therapy with tamoxifen in hormone receptor positive tumours, and ...
5
Optimising endocrine therapy in postmenopausal women with advanced breast cancer
... 2012 Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast[r] ...
26